MedPath

CDA Research Group, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

5

Active:0
Completed:2

Trial Phases

2 Phases

Early Phase 1:2
Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (60.0%)
Early Phase 1
2 (40.0%)

3VM1001 Cream for the Treatment of Pain Associated With Post Herpetic Neuralgia (PHN)

Early Phase 1
Completed
Conditions
Treatment of PHN
Interventions
Drug: 3VM1001
Other: Placebo
First Posted Date
2018-02-05
Last Posted Date
2018-07-10
Lead Sponsor
CDA Research Group, Inc.
Target Recruit Count
28
Registration Number
NCT03421613
Locations
🇺🇸

Medex Healthcare Research, Inc., Chicago, Illinois, United States

🇺🇸

Medex Healthcare Reasearch, Inc., New York, New York, United States

3VM for Treatment of Chronic Osteoarthritis Knee Pain

Phase 1
Completed
Conditions
Arthritis, Degenerative
First Posted Date
2017-05-05
Last Posted Date
2018-07-06
Lead Sponsor
CDA Research Group, Inc.
Target Recruit Count
150
Registration Number
NCT03142178
Locations
🇺🇸

Optimed Research, LTD, Columbus, Ohio, United States

Assessment of the Safety and Efficacy of 3VM1001 Cream for Treatment of Chronic Pain Caused by Knee Osteoarthritis.

Phase 1
Conditions
Osteoarthritis of Knee
Interventions
Drug: 3VM1001
Drug: Placebo for 3VM1001
First Posted Date
2015-01-06
Last Posted Date
2015-08-21
Lead Sponsor
CDA Research Group, Inc.
Target Recruit Count
50
Registration Number
NCT02332148

LUXSOL(TM) Topical Cream for the Treatment of Symptomatic Bacterial Vaginosis; A Proof of Concept Study

Early Phase 1
Terminated
Conditions
Bacterial Vaginosis (BV)
Interventions
Drug: LUXSOL copper containing cream
First Posted Date
2014-07-22
Last Posted Date
2018-04-05
Lead Sponsor
CDA Research Group, Inc.
Target Recruit Count
50
Registration Number
NCT02197182
Locations
🇺🇸

Harper University Hospital Department of Infectious Diseases, Detroit, Michigan, United States

🇺🇸

Temple University Hospital Department of OB/GYN, Philadelphia, Pennsylvania, United States

GoldenCareTM for the Treatment of Bacterial Vaginosis

Phase 1
Terminated
Conditions
Bacterial Vaginosis
Interventions
Drug: GoldenCare
First Posted Date
2013-01-08
Last Posted Date
2015-02-03
Lead Sponsor
CDA Research Group, Inc.
Target Recruit Count
8
Registration Number
NCT01762670
Locations
🇺🇸

Harper University Hospital Department of Infectious Diseases, Detroit, Michigan, United States

🇺🇸

Temple University Hospital Department of OB/GYN, Philadelphia, Pennsylvania, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.